The Multicenter Italian Trial Assesses the Performance of FDG-PET /CT Related to Pre-Test Cancer Risk in Patients with Solitary Pulmonary Nodules and Introduces a Segmental Thoracic Diagnostic Strategy.


Journal

Current radiopharmaceuticals
ISSN: 1874-4729
Titre abrégé: Curr Radiopharm
Pays: United Arab Emirates
ID NLM: 101468718

Informations de publication

Date de publication:
2020
Historique:
received: 09 01 2019
revised: 13 02 2019
accepted: 11 11 2019
pubmed: 19 3 2020
medline: 3 9 2021
entrez: 19 3 2020
Statut: ppublish

Résumé

The Italian Tailored Assessment of Lung Indeterminate Accidental Nodule (ITALIAN) trial is a trial drawn to determine the performance of 18F-FDG-PET/CT in patients with solitary pulmonary nodules (SPN), stratified for a different kind of risk. An additional end-point was to compare the diagnostic information and estimated dosimetry, provided by a segmental PET/CT (s-PET/CT) acquisition instead of a whole body PET/CT (wb-PET/CT), in order to evaluate if segmental thoracic PET/CT can be used in patients with SPN. 18F-FDG PET/CT of 502 patients, stratified for pre-test cancer risk, was retrospectively analyzed. FDG uptake in SPN was assessed by a 4-point scoring (4PS) system and a semiquantitative analysis using the ratio between SUVmax in SPN and SUVmean in mediastinal blood pool (BP), and between SUVmax in SPN and SUVmean in the liver (L). Histopathology and/or follow-up data were used as a standard of reference. Data obtained on the thoracic part of wb-PET/CT, defined as s - PET/CT, were compared with those deriving from wb-PET/CT. SPNs were malignant in 180 patients (36%), benign in 175 (35%), and indeterminate in 147 (29%). The 355 patients diagnosed with a definitive SPN nature (malignant or benign) were considered for the analysis of PET performance. Sensitivity, specificity, positive (PPV) and negative (NPV) predictive values, and accuracy were 85.6%, 85.7%, 86%, 85.2%, and 85.6%, respectively. Sensitivity and PPV were higher in intermediate and high-risk patients. 18F-FDG uptake indicative of thoracic and extra-thoracic lesions was detectable in 13% and 3% of the patients. Compared to wb-PET/CT, s-PET/CT could save about 2/3 of 18F-FDG dose, radiation exposure or scan-time, without affecting the clinical impact of PET/CT. In patients with SPN, the pre-test likelihood of malignancy stratification allows to better define PET clinical setting and its diagnostic power. In subjects with low-intermediate pre-test likelihood of malignancy, s-PET/CT might be planned in advance. The adoption of this segmental strategy could reduce radiation exposure, scan-time, and might allow individually targeted protocols.

Identifiants

pubmed: 32186274
pii: CRP-EPUB-105350
doi: 10.2174/1874471013666200318142210
pmc: PMC8206189
doi:

Substances chimiques

Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

243-248

Informations de copyright

Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Références

N Engl J Med. 2011 Aug 4;365(5):395-409
pubmed: 21714641
Chest. 2003 Nov;124(5):1828-33
pubmed: 14605056
Eur J Nucl Med Mol Imaging. 2017 Feb;44(2):346-347
pubmed: 27909768
Chest. 2013 May;143(5 Suppl):e93S-e120S
pubmed: 23649456
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):5-7
pubmed: 27624189
Radiology. 2008 Mar;246(3):772-82
pubmed: 18235105
Lancet Oncol. 2011 Sep;12(10):933-80
pubmed: 21958503
Radiology. 2008 Mar;246(3):697-722
pubmed: 18195376
J Nucl Med. 2006 May;47(5):885-95
pubmed: 16644760
Eur J Nucl Med Mol Imaging. 2018 Oct;45(11):1898-1907
pubmed: 29736699
Quant Imaging Med Surg. 2013 Dec;3(6):316-26
pubmed: 24404446
N Engl J Med. 2009 Mar 5;360(10):1030-7
pubmed: 19264694
Radiology. 2005 Nov;237(2):395-400
pubmed: 16244247
JAMA. 2001 Feb 21;285(7):914-24
pubmed: 11180735
N Engl J Med. 2013 Sep 5;369(10):910-9
pubmed: 24004118
Radiol Med. 2016 Mar;121(3):218-24
pubmed: 26541882
Thorax. 2015 Aug;70 Suppl 2:ii1-ii54
pubmed: 26082159
Eur J Radiol. 2015 Oct;84(10):2032-7
pubmed: 26094866
Eur J Radiol. 2017 May;90:188-191
pubmed: 28583632
J Nucl Med. 2008 Feb;49(2):179-85
pubmed: 18199626
Eur J Nucl Med Mol Imaging. 2017 Jan;44(1):1-4
pubmed: 27695909
JAMA Intern Med. 2014 Feb 1;174(2):269-74
pubmed: 24322569
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219
Eur J Nucl Med Mol Imaging. 2017 Aug;44(Suppl 1):4-16
pubmed: 28687866

Auteurs

Marco Spadafora (M)

Nuclear Medicine Unit, Ospedale del Mare, Naples, Italy
Nuclear Medicine Unit, Ospedale San Giuseppe Moscati, Avellino, Italy

Laura Evangelista (L)

Nuclear Medicine Unit, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy

Salvatore Fiordoro (S)

Nuclear Medicine Unit, Ospedale del Mare, Naples, Italy

Francesco Porcaro (F)

Nuclear Medicine Unit, Ospedale del Mare, Naples, Italy

Marilena Sicignano (M)

Nuclear Medicine Unit, Ospedale del Mare, Naples, Italy

Luigi Mansi (L)

Section Health and Development, Interuniversity Research Center for Sustainability (CIRPS), Naples, Italy

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH